Physician profile
Jonathan Scogin
NPI 1811305949
$3,966.54
in general payments reported to CMS, 2019-2025
22 companies · $1,288 in 2025
The $1,288 reported for 2025 was more than what 98% of Vision Therapy providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2021: $504 · 2022: $521 · 2023: $686 · 2024: $433 · 2025: $1,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,407.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $757.83 | 2019-2025 | Precision7, Precision 1, Total30 |
| Biotissue Holdings INC. | $425.80 | 2022-2025 | |
| Abbvie INC. | $323.58 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $305.92 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Oyster Point Pharma, INC. | $259.88 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $259.35 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $234.99 | 2022-2023 | Photrexa Cross-Linking Kit |
| Johnson & Johnson Vision Care, INC. | $197.05 | 2019-2025 | |
| Allergan, INC. | $183.22 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $169.61 | 2022-2025 | Acthar |
| Rxsight INC | $163.93 | 2022-2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Alimera Sciences, INC. | $155.72 | 2019-2024 | Yutiq, Iluvien |
| Apellis Pharmaceuticals, INC. | $128.09 | 2024-2025 | Syfovre |
| Optos, INC. | $125.29 | 2021 | |
| Sun Pharmaceutical Industries INC. | $60.48 | 2023-2025 | Cequa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $57.53 | 2023-2024 | Izervay |
| Coopervision INC. | $54.41 | 2023-2024 | Myday Contact Lens, Biofinity Contact Lens |
| Ani Pharmaceuticals, INC. | $34.52 | 2025 | Purified Cortrophin Gel |
| Aerie Pharmaceuticals, INC. | $32.30 | 2021 | |
| Shire North American Group INC | $24.01 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.03 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Scogin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.